Genedata and Schering Expand Genomics-based Drug Discovery Collaboration Worldwide

16-Jan-2004

Genedata and Schering AG, Germany, announced that they are widening the scope of their four-year collaboration. In order to strengthen their global drug discovery program, Schering has extended the license for Expressionist, the Genedata computational system for large-scale gene expression analysis in the pharmaceutical industry. Schering's move to implement Expressionist across several Schering sites validates the scalability of the software system as a platform for organization-wide data analysis. Under the terms of the agreement, Genedata will also provide consulting services to ensure the continued smooth integration of Expressionist into Schering's global research landscape.

"Since 1999, we have been partnering with Genedata. Therefore, we know from experience that Expressionist is the most comprehensive system for microarray data analysis, data management, and results management. To fully integrate their system into our drug discovery pipeline, we have initiated collaborations with Genedata in target identification, toxicology, and pharmacology. We are also joining forces to build a custom database system that will integrate our research results worldwide," says Dr. Hans-Dieter Pohlenz, Head of Genomics and Bioinformatics within Schering Research Center Europe.

"Schering's decision to implement Expressionist as a key element of their global research database demonstrates the trust they have in the technical and scientific capabilities of Expressionist. Expressionist will support their project-based, international research teams, but will also help them comply with the rigorous standards prescribed by regulatory agencies. We are looking forward to working closely with Schering on the scientific global implementation," states Dr. Andreas Hohn, Director of Business Development at Genedata.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances